Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "NIBIT-M2 Trial 7-Year Outcomes and QoL of Nivolumab + Ipilimumab in Melanoma With Asymptomatic Brain Metastases"

71 views
October 31, 2023
0 Comments
Login to view comments. Click here to Login
Skin